Ferrer Partners with Prilenia for Pridopidine Co-Development
April 28, 2025
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing